Funding agencies: U.S. Army Medical Research and Materiel Command (W81XWH-09-0708 and W81XWH-13-1-0025 to J.A.P.); NIH (U01 NS082157 and R01 NS064155 to C.R.S.). The Harvard Biomarker Study is supported by the Harvard NeuroDiscovery Center.
Specific splice variants are associated with Parkinson's disease
Version of Record online: 20 SEP 2013
© 2013 Movement Disorder Society
Volume 28, Issue 12, pages 1724–1727, October 2013
How to Cite
Santiago, J. A., Scherzer, C. R., Harvard Biomarker Study and Potashkin, J. A. (2013), Specific splice variants are associated with Parkinson's disease. Mov. Disord., 28: 1724–1727. doi: 10.1002/mds.25635
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue online: 25 OCT 2013
- Version of Record online: 20 SEP 2013
- Manuscript Accepted: 14 JUL 2013
- Manuscript Revised: 14 MAY 2013
- Manuscript Received: 22 MAR 2013
- Parkinson's disease;
- gene expression
Diagnosis of Parkinson's disease (PD) currently relies on assessment of motor symptoms. Recently, sensitive, specific, and readily available splice variant–specific biomarkers were identified in peripheral blood from participants in the Diagnostic and Prognostic Biomarkers in Parkinson Disease study.
Here we test for an association between candidate splice variant biomarkers and PD in blood of an independent population of cases and controls nested in the Harvard NeuroDiscovery Center Biomarker Study.
Expression of 7 out of 13 candidate biomarkers was dysregulated in whole cellular blood of patients with PD.
These results support the view that differential expression of a subset of splice-variant markers in blood is associated with PD. Further evaluation in untreated, de novo patients and at-risk subjects is warranted. © 2013 International Parkinson and Movement Disorder Society